Pharma-Bio Serv (PBSV) Cost of Revenue (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Cost of Revenue for 16 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 12.67% year-over-year to $1.8 million; the trailing twelve-month figure through Apr 2026 stood at $6.2 million (down 7.89% YoY), and the FY2025 full-year result was $6.1 million, down 12.9% from the prior year.
• Cost of Revenue rose to $1.8 million in Q2 2026 per PBSV's latest filing, from $1.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.8 million in Q1 2022 and bottomed at $1.4 million in Q3 2025.
• Historically, Cost of Revenue has averaged $2.4 million across 5 years, with a median of $1.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue climbed 18.95% in 2022, then plunged 45.31% in 2024.
• Over 5 years, Cost of Revenue stood at $3.5 million in 2022, then dropped by 24.4% to $2.7 million in 2023, then slumped by 39.79% to $1.6 million in 2024, then fell by 12.82% to $1.4 million in 2025, then climbed by 28.57% to $1.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1.8 million, $1.6 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.